Amicus Therapeutics, Inc. Expected to Earn FY2017 Earnings of ($1.77) Per Share (FOLD)
Amicus Therapeutics, Inc. (NASDAQ:FOLD) – Equities researchers at Leerink Swann dropped their FY2017 EPS estimates for Amicus Therapeutics in a research note issued on Wednesday. Leerink Swann analyst J. Schwartz now forecasts that the biopharmaceutical company will earn ($1.77) per share for the year, down from their previous estimate of ($1.31). Leerink Swann currently has a “Buy” rating and a $20.00 target price on the stock. Leerink Swann also issued estimates for Amicus Therapeutics’ Q4 2017 earnings at ($0.34) EPS, FY2018 earnings at ($1.24) EPS, FY2019 earnings at ($0.91) EPS and FY2020 earnings at ($0.71) EPS.
Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.10). Amicus Therapeutics had a negative net margin of 1,092.37% and a negative return on equity of 63.54%. The business had revenue of $10.90 million for the quarter, compared to the consensus estimate of $9.02 million. During the same quarter last year, the business earned ($0.33) EPS. Amicus Therapeutics’s revenue for the quarter was up 419.0% compared to the same quarter last year.
Several other brokerages also recently weighed in on FOLD. Zacks Investment Research downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, October 12th. Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and issued a $17.00 target price on shares of Amicus Therapeutics in a research note on Friday, October 6th. Chardan Capital reissued a “buy” rating and issued a $18.50 target price (up previously from $16.50) on shares of Amicus Therapeutics in a research note on Thursday, October 5th. Robert W. Baird reissued an “outperform” rating and issued a $18.00 target price (up previously from $16.00) on shares of Amicus Therapeutics in a research note on Wednesday, October 4th. Finally, J P Morgan Chase & Co reissued an “overweight” rating on shares of Amicus Therapeutics in a research note on Wednesday, October 4th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Amicus Therapeutics has a consensus rating of “Buy” and a consensus price target of $17.81.
Amicus Therapeutics (FOLD) opened at $13.00 on Monday. Amicus Therapeutics has a 12-month low of $4.41 and a 12-month high of $16.60. The company has a quick ratio of 6.22, a current ratio of 6.32 and a debt-to-equity ratio of 0.39.
In related news, CEO John F. Crowley sold 71,735 shares of the firm’s stock in a transaction dated Wednesday, October 18th. The shares were sold at an average price of $14.75, for a total value of $1,058,091.25. Following the transaction, the chief executive officer now owns 380,723 shares of the company’s stock, valued at approximately $5,615,664.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Michael Raab sold 10,000 shares of the firm’s stock in a transaction dated Thursday, October 12th. The stock was sold at an average price of $14.25, for a total transaction of $142,500.00. The disclosure for this sale can be found here. Insiders sold a total of 628,224 shares of company stock worth $9,024,003 in the last ninety days. 3.40% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of FOLD. Strs Ohio purchased a new position in Amicus Therapeutics during the 3rd quarter valued at about $102,000. Teacher Retirement System of Texas increased its position in Amicus Therapeutics by 1.7% during the 2nd quarter. Teacher Retirement System of Texas now owns 10,243 shares of the biopharmaceutical company’s stock valued at $103,000 after purchasing an additional 169 shares during the period. DORCHESTER WEALTH MANAGEMENT Co purchased a new position in Amicus Therapeutics during the 2nd quarter valued at about $111,000. Tudor Investment Corp ET AL purchased a new position in Amicus Therapeutics during the 2nd quarter valued at about $124,000. Finally, Aperio Group LLC increased its position in Amicus Therapeutics by 13.5% during the 2nd quarter. Aperio Group LLC now owns 13,986 shares of the biopharmaceutical company’s stock valued at $141,000 after purchasing an additional 1,663 shares during the period.
About Amicus Therapeutics
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Stock Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related stocks with our FREE daily email newsletter.